As shown in Figure 4A, the top ten targets for EB treatment of glaucoma include AKT serine/threonine kinase 1 (AKT1), estrogen receptor 1 (ESR1), epidermal growth factor receptor (EGFR), BCL2 apoptosis regulator (BCL2), hypoxia inducible factor 1 subunit alpha (HIF1A), SRC proto-oncogene, non-receptor tyrosine kinase (SRC), heat shock protein 90 alpha family class a member 1 (HSP90AA1), prostaglandin-endoperoxide synthase 2 (PTGS2), mitogen-activated protein kinase 3 (MAPK3), and heat shock protein 90 alpha family class b member 1 (HSP90AB1). This evidence concerns the gene MAP2K3 and glaucoma.